Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure
Fig 2
Initial screening results with multiplex serology and PCR to identify T. cruzi-negative dogs to enroll in the prophylaxis study.
(A) Schematic representation of dog screening and prophylaxis trial. Heatmaps of antibody levels (mean fluorescence intensity; MFI) and qPCR measurement of T. cruzi DNA in blood were used to classify dogs as uninfected (B), T. cruzi-infected (C), or seronegative but with a blood PCR result that did not reach the cut-off for being considered positive (D). Recombinant T. cruzi proteins are defined in the Materials and Methods; lysate = a sonicate of T. cruzi trypomastigotes and amastigotes; GFP = recombinant green fluorescent protein (negative antigen control); Parvo = Parvovirus vaccine antigen (positive serological control).